C57BL/6JCya-Pdgfrl^em1/Cya

Pdgfrl, or platelet-derived growth factor receptor-like, is regarded as a tumor suppressor gene [2,3,5]. It may be involved in various biological processes. For example, in chondrocytes, it controls proliferation and differentiation [2]. The PDGF family, to which Pdgfrl belongs, is associated with angiogenesis and steroid hormone production [4].

In endometriosis, Pdgfrl was identified as one of the five biomarkers, along with CXCL12, AGTR1, PTGER3, and S1PR1, through bioinformatics analysis. These biomarkers were selected from a relatively suitable SVM model for endometriosis prediction, and the nomogram based on them had a robust ability to predict the disease [1]. In chondrocytes, overexpression of Pdgfrl promoted the proliferation of chondrocytic HCS-2/8 cells but decreased the expression of chondrocyte differentiation marker genes [2]. In colorectal cancer, the expression of Pdgfrl was higher in normal tissues than in cancer tissues, and recombinant human Pdgfrl could inhibit the proliferation and invasion of CRC HCT-116 cells and arrest the cell cycle at the G0/G1 phase [3]. In hepatocellular carcinoma, Pdgfrl, a potential target of regorafenib, was increased after cumulative treatment of regorafenib and radiotherapy. Pdgfrl suppressed HCC cell proliferation and promoted apoptosis by inhibiting the STAT3 pathway activation [5].

In conclusion, Pdgfrl plays diverse roles in different cell types and diseases. It has potential as a biomarker in endometriosis, and its tumor-suppressing function is evident in colorectal and hepatocellular carcinomas. In chondrocytes, it shows a unique function in regulating cell proliferation and differentiation. The study of Pdgfrl provides valuable insights into understanding the molecular mechanisms of these diseases and potential therapeutic strategies.

References:

1. Jiang, Hong, Zhang, Xia, Wu, Yalan, Chen, Lihong, He, Xinqin. 2022. Bioinformatics identification and validation of biomarkers and infiltrating immune cells in endometriosis. In Frontiers in immunology, 13, 944683. doi:10.3389/fimmu.2022.944683. https://pubmed.ncbi.nlm.nih.gov/36524127/

2. Kawata, Kazumi, Kubota, Satoshi, Eguchi, Takanori, Kawaki, Harumi, Takigawa, Masaharu. 2017. A Tumor Suppressor Gene Product, Platelet-Derived Growth Factor Receptor-Like Protein Controls Chondrocyte Proliferation and Differentiation. In Journal of cellular biochemistry, 118, 4033-4044. doi:10.1002/jcb.26059. https://pubmed.ncbi.nlm.nih.gov/28407304/

3. Guo, Feng-Jie, Zhang, Wei-Jia, Li, Ya-Lin, Xie, Ping-Li, Li, Guan-Cheng. . Expression and functional characterization of platelet-derived growth factor receptor-like gene. In World journal of gastroenterology, 16, 1465-72. doi:. https://pubmed.ncbi.nlm.nih.gov/20333786/

4. McDerment, N A, Hocking, P M, Dunn, I C. 2015. Identification and characterisation of alternative transcriptional variants of PDGFRL in two lines of commercial poultry. In Animal genetics, 46, 498-505. doi:10.1111/age.12327. https://pubmed.ncbi.nlm.nih.gov/26202218/

5. Kuang, Shuwen, Zhang, Jiajun, Huang, Ning, Wang, Liming, Liu, Mei. 2024. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. In Molecular carcinogenesis, 63, 1738-1749. doi:10.1002/mc.23769. https://pubmed.ncbi.nlm.nih.gov/38837427/